


Ask a doctor about a prescription for IVABRADINE KERN PHARMA 7.5 mg TABLETS
Patient Information: Prospect
Ivabradina Kern Pharma 7.5 mg tablets EFG
Read the entire prospect carefully before starting to take this medication, as it contains important information for you.
Contents of the prospect:
Ivabradina is a heart medication used to treat:
About stable angina pectoris (normally known as "angina")
Stable angina pectoris is a heart disease that occurs when the heart does not receive enough oxygen. It usually appears between the ages of 40 and 50. The most common symptom of angina is chest pain or discomfort. Angina is more likely to occur when the heart beats faster in situations such as exercise, emotion, exposure to cold, or after eating. This increase in heart rate can cause chest pain in people with angina.
About chronic heart failure:
Chronic heart failure is a heart disease that occurs when the heart cannot pump enough blood to the rest of the body. The most common symptoms of heart failure are difficulty breathing, fatigue, tiredness, and swelling of the ankles.
Ivabradina works primarily by reducing the heart rate by a few beats per minute. This reduces the heart's need for oxygen, especially in situations where angina attacks are more likely to occur. In this way, Ivabradina tablets help control and reduce the number of angina attacks.
Additionally, since elevated heart rate negatively affects heart function and vital prognosis in patients with chronic heart failure, the specific heart rate-lowering action of Ivabradina helps improve heart function and vital prognosis in these patients.
Do not take Ivabradina tablets
Warnings and precautions
Consult your doctor or pharmacist before starting to take Ivabradina tablets:
If you meet any of these conditions, consult your doctor immediately before or during treatment with Ivabradina tablets.
Children
Ivabradina tablets are not intended for use in children and adolescents under 18 years of age.
Using Ivabradina tablets with other medications
Tell your doctor or pharmacist if you are taking, have recently taken, or may need to take any other medication.
Make sure to inform your doctor if you are taking any of the following medications, as a dose adjustment of Ivabradina tablets or monitoring may be necessary:
Taking Ivabradina tablets with food and drinks
Avoid grapefruit juice during treatment with Ivabradina tablets.
Pregnancy and breastfeeding
Do not take Ivabradina tablets if you are pregnant or plan to become pregnant (see "Do not take Ivabradina tablets").
If you are pregnant and have taken Ivabradina tablets, consult your doctor.
Do not take Ivabradina tablets if you are of childbearing age and do not use reliable contraceptive methods (see "Do not take Ivabradina tablets").
Do not take Ivabradina tablets if you are breastfeeding (see "Do not take Ivabradina tablets"). Talk to your doctor if you are breastfeeding or plan to start breastfeeding, as you should stop breastfeeding if you are taking Ivabradina tablets.
If you are pregnant, breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Driving and using machines
Ivabradina tablets may cause transient visual phenomena (a brief increase in brightness, see "Possible adverse effects"). If this happens, be careful when driving or using machinery in situations where sudden changes in light intensity may occur, especially when driving at night.
Ivabradina Kern Pharma contains lactose and glucose
This medication contains lactose. If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
This medication contains glucose (from maltodextrin). If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
Follow the administration instructions for this medication exactly as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.
Ivabradina tablets should be taken with breakfast and dinner.
If you are being treated for stable angina pectoris
The initial dose should not exceed one 5 mg Ivabradina tablet twice a day. If you still have symptoms of angina and have tolerated the 5 mg dose twice a day, the dose can be increased. The maintenance dose should not exceed 7.5 mg twice a day. Your doctor will prescribe the correct dose for you. The usual dose is one tablet in the morning and one tablet in the evening. In some cases (e.g., if you are an elderly patient), your doctor may prescribe half the dose, i.e., half a 5 mg Ivabradina tablet (corresponding to 2.5 mg of Ivabradina) in the morning and half a 5 mg tablet in the evening.
If you are being treated for chronic heart failure
The recommended initial dose is one 5 mg Ivabradina tablet twice a day, which can be increased if necessary to one 7.5 mg Ivabradina tablet twice a day. Your doctor will decide the suitable dose for you. The usual dose is one tablet in the morning and one tablet in the evening. In some cases (e.g., if you are an elderly patient), your doctor may prescribe half the dose, i.e., half a 5 mg Ivabradina tablet (corresponding to 2.5 mg of Ivabradina) in the morning and half a 5 mg tablet in the evening.
If you take more Ivabradina tablets than you should
An overdose of Ivabradina tablets can make you feel tired or have difficulty breathing because your heart is beating too slowly. If this happens, contact your doctor immediately.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take Ivabradina tablets
If you forget to take a dose of Ivabradina tablets, take the next dose at the scheduled time. Do not take a double dose to make up for missed doses.
The printed calendar on the blister pack containing the tablets will help you remember when you last took an Ivabradina tablet.
If you stop taking Ivabradina tablets
Generally, treatment for angina pectoris or chronic heart failure is lifelong, so you should consult your doctor before stopping this medication.
If you think the effect of Ivabradina tablets is too strong or too weak, tell your doctor or pharmacist.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause adverse effects, although not everyone will experience them.
The frequency of the possible adverse effects listed below is defined using the following system:
Very common: may affect more than 1 in 10 people.
Common: may affect up to 1 in 10 people.
Uncommon: may affect up to 1 in 100 people.
Rare: may affect up to 1 in 1,000 people.
Very rare: may affect up to 1 in 10,000 people.
Frequency not known: the frequency cannot be estimated from the available data.
The most common adverse reactions with this medication are dose-dependent and related to its mechanism of action:
Very common:
Transient visual phenomena (brief moments of increased brightness, usually caused by sudden changes in light intensity). They can also be described as a halo, flashes of color, image decomposition, or multiple images. These usually appear during the first two months of treatment, after which they may occur repeatedly and resolve during or after treatment.
Common:
Modification of heart function (symptoms are a slowing of the heart rate). This occurs especially in the first 2 to 3 months after starting treatment.
Other adverse effects have also been reported:
Common:
Irregular rapid heart contraction, sensation of abnormal heartbeat, uncontrolled high blood pressure, headache, dizziness, and blurred vision (cloudy vision).
Uncommon:
Palpitations and extra heartbeats, sensation of dizziness (nausea), constipation, diarrhea, abdominal pain, sensation of spinning (vertigo), difficulty breathing (dyspnea), muscle cramps, changes in laboratory tests: elevated blood uric acid levels, excess eosinophils (a type of white blood cell), and elevated creatinine levels in blood (a muscle degradation product), skin rash, angioedema (such as facial swelling, tongue or throat swelling, difficulty breathing or swallowing), low blood pressure, fainting, feeling of fatigue, feeling of weakness, abnormal electrocardiogram, double vision, visual disturbance.
Rare:
Hives, itching, skin redness, malaise.
Very rare:
Irregular heartbeats.
Reporting adverse effects
If you experience any adverse effects, consult your doctor or pharmacist, even if they are not listed in this prospect. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medications: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date shown on the packaging, after CAD. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medications should not be disposed of through wastewater or household waste. Deposit the packaging and unused medications at the SIGRE collection point in the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and unused medications. This will help protect the environment.
Composition of Ivabradina Kern Pharma tablets
Each tablet contains 7.5 mg of ivabradina (equivalent to 8.085 mg of ivabradina as hydrochloride).
Appearance of the product and package contents
Ivabradina Kern Pharma 7.5 mg are white or almost white, round, biconvex, smooth tablets on both sides.
The tablets are presented in PA/Al/PVC-Aluminum blister packs, calendarized in packages of 56 tablets.
Marketing authorization holder and manufacturer
Marketing authorization holder:
Kern Pharma, S.L.
Venus, 72 – Pol. Ind. Colón II
08228 Terrassa – Barcelona
Spain
Manufacturer:
Laboratorios Alter, S.A.
C/ Mateo Inurria 30
28036 Madrid
Spain
Date of the last revision of this prospect:October 2016.
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es.
The average price of IVABRADINE KERN PHARMA 7.5 mg TABLETS in October, 2025 is around 43.27 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for IVABRADINE KERN PHARMA 7.5 mg TABLETS – subject to medical assessment and local rules.